Blue Fin Capital Inc. Has $1.01 Million Holdings in Pfizer Inc. (NYSE:PFE)

Blue Fin Capital Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 19.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 34,970 shares of the biopharmaceutical company’s stock after selling 8,704 shares during the period. Blue Fin Capital Inc.’s holdings in Pfizer were worth $1,007,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in PFE. Trifecta Capital Advisors LLC raised its position in Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares in the last quarter. Confluence Wealth Services Inc. lifted its position in shares of Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 342 shares during the last quarter. Carr Financial Group Corp grew its position in Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 355 shares during the last quarter. Caldwell Sutter Capital Inc. raised its stake in Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after acquiring an additional 364 shares in the last quarter. Finally, Lafayette Investments Inc. boosted its stake in shares of Pfizer by 2.2% in the 3rd quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock valued at $579,000 after purchasing an additional 368 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.4 %

Pfizer stock traded up $0.11 during midday trading on Friday, reaching $27.81. The stock had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. The company has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $28.21. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.23 earnings per share. As a group, equities research analysts expect that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.